AtriCure [ATRC] vs Becton, Dickinson [BDX] Detailed Stock Comparison
AtriCure
NASDAQ
Loading...
Becton, Dickinson
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: AtriCure wins in 7 metrics, Becton, Dickinson wins in 11 metrics, with 0 ties. Becton, Dickinson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | AtriCure | Becton, Dickinson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -36.64 | 35.46 | AtriCure |
| Price-to-Book Ratio | 3.72 | 2.18 | Becton, Dickinson |
| Debt-to-Equity Ratio | 16.63 | 75.93 | AtriCure |
| PEG Ratio | 1.56 | 1.86 | AtriCure |
| EV/EBITDA | -120.13 | 12.52 | AtriCure |
| Profit Margin (TTM) | -7.27% | 7.41% | Becton, Dickinson |
| Operating Margin (TTM) | -4.55% | 17.81% | Becton, Dickinson |
| EBITDA Margin (TTM) | N/A | 17.81% | N/A |
| Return on Equity | -7.85% | 6.18% | Becton, Dickinson |
| Return on Assets (TTM) | -3.53% | 3.96% | Becton, Dickinson |
| Free Cash Flow (TTM) | $-11.26M | $3.07B | Becton, Dickinson |
| Dividend Yield | N/A | 1.80% | N/A |
| 1-Year Return | 25.99% | -18.73% | AtriCure |
| Price-to-Sales Ratio (TTM) | 3.46 | 2.59 | Becton, Dickinson |
| Enterprise Value | $1.69B | $74.08B | Becton, Dickinson |
| EV/Revenue Ratio | 3.38 | 3.46 | AtriCure |
| Gross Profit Margin (TTM) | 74.54% | 47.81% | AtriCure |
| Revenue per Share (TTM) | $11 | $74 | Becton, Dickinson |
| Earnings per Share (Diluted) | $-0.77 | $5.46 | Becton, Dickinson |
| Beta (Stock Volatility) | 1.60 | 0.28 | Becton, Dickinson |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
AtriCure vs Becton, Dickinson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| AtriCure | -0.23% | -1.11% | 0.12% | 9.60% | 5.74% | 14.51% |
| Becton, Dickinson | -0.84% | 4.88% | 2.11% | 9.91% | -12.63% | -14.52% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| AtriCure | 25.99% | -9.23% | -15.82% | 90.01% | 329.75% | 145.49% |
| Becton, Dickinson | -18.73% | -13.05% | -16.37% | 44.06% | 165.47% | 282.86% |
News Based Sentiment: AtriCure vs Becton, Dickinson
AtriCure
News based Sentiment: MIXED
September presented a mixed bag for AtriCure, with strong Q3 earnings and a new product launch offset by continued insider selling and conservative guidance. While revenue growth is encouraging, the lack of profitability and executive sentiment create uncertainty, making it a significant but not overwhelmingly positive month for investors.
Becton, Dickinson
News based Sentiment: POSITIVE
Becton Dickinson had a strong month driven by a significant earnings beat, upward guidance revision, and a strategic partnership focused on the growing pharmacy automation market. While insider selling exists, the overall narrative is positive, supported by high institutional ownership and positive analyst coverage.
Performance & Financial Health Analysis: AtriCure vs Becton, Dickinson
| Metric | ATRC | BDX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.78B | $55.67B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 313,868 | 1,421,540 |
| 90 Day Avg. Volume | 404,019 | 1,589,433 |
| Last Close | $34.73 | $191.99 |
| 52 Week Range | $25.57 - $43.11 | $163.33 - $251.99 |
| % from 52W High | -19.44% | -23.81% |
| All-Time High | $89.18 (Nov 01, 2021) | $287.32 (Jul 24, 2023) |
| % from All-Time High | -61.06% | -33.18% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.17% | 0.10% |
| Quarterly Earnings Growth | 0.17% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | -0.07% | 0.07% |
| Operating Margin (TTM) | -0.05% | 0.18% |
| Return on Equity (TTM) | -0.08% | 0.06% |
| Debt to Equity (MRQ) | 16.63 | 75.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $9.35 | $88.87 |
| Cash per Share (MRQ) | $2.37 | $2.64 |
| Operating Cash Flow (TTM) | $36.43M | $3.25B |
| Levered Free Cash Flow (TTM) | $1.65M | $3.37B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.80% |
| Last 12-Month Dividend | N/A | $3.03 |
Valuation & Enterprise Metrics Analysis: AtriCure vs Becton, Dickinson
| Metric | ATRC | BDX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -36.64 | 35.46 |
| Forward P/E | -55.25 | 12.31 |
| PEG Ratio | 1.56 | 1.86 |
| Price to Sales (TTM) | 3.46 | 2.59 |
| Price to Book (MRQ) | 3.72 | 2.18 |
| Market Capitalization | ||
| Market Capitalization | $1.78B | $55.67B |
| Enterprise Value | $1.69B | $74.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.38 | 3.46 |
| Enterprise to EBITDA | -120.13 | 12.52 |
| Risk & Other Metrics | ||
| Beta | 1.60 | 0.28 |
| Book Value per Share (MRQ) | $9.35 | $88.87 |
Financial Statements Comparison: AtriCure vs Becton, Dickinson
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ATRC | BDX |
|---|---|---|
| Revenue/Sales | $136.14M | $5.51B |
| Cost of Goods Sold | $34.66M | $2.88B |
| Gross Profit | $101.48M | $2.63B |
| Research & Development | $29.28M | $297.00M |
| Operating Income (EBIT) | $-6.19M | $979.00M |
| EBITDA | $732,000 | $1.57B |
| Pre-Tax Income | $-5.93M | $703.00M |
| Income Tax | $261,000 | $129.00M |
| Net Income (Profit) | $-6.19M | $574.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ATRC | BDX |
|---|---|---|
| Cash & Equivalents | $117.80M | $667.00M |
| Total Current Assets | $271.26M | $8.67B |
| Total Current Liabilities | $68.84M | $7.69B |
| Long-Term Debt | $74.34M | $17.67B |
| Total Shareholders Equity | $464.49M | $25.24B |
| Retained Earnings | $-414.69M | $16.15B |
| Property, Plant & Equipment | $47.77M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ATRC | BDX |
|---|---|---|
| Operating Cash Flow | $14.89M | $941.00M |
| Capital Expenditures | $-2.66M | N/A |
| Free Cash Flow | $13.96M | $35.00M |
| Debt Repayment | $-292,000 | $-1.00M |
| Common Stock Repurchase | $-406,000 | $0 |
Short Interest & Institutional Ownership Analysis
| Metric | ATRC | BDX |
|---|---|---|
| Shares Short | 2.06M | 4.28M |
| Short Ratio | 4.88 | 2.41 |
| Short % of Float | 0.04% | 0.02% |
| Average Daily Volume (10 Day) | 313,868 | 1,421,540 |
| Average Daily Volume (90 Day) | 404,019 | 1,589,433 |
| Shares Outstanding | 48.87M | 289.10M |
| Float Shares | 47.93M | 286.00M |
| % Held by Insiders | 0.03% | 0.01% |
| % Held by Institutions | 1.01% | 0.92% |
Dividend Analysis & Yield Comparison: AtriCure vs Becton, Dickinson
| Metric | ATRC | BDX |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.03 |
| Last 12-Month Dividend Yield | N/A | 1.80% |
| 3-Year Avg Annual Dividend | N/A | $3.16 |
| 3-Year Avg Dividend Yield | N/A | 0.40% |
| 3-Year Total Dividends | N/A | $9.48 |
| Ex-Dividend Date | N/A | Mar 10, 2025 |